Chemie und Prozesstechnik
Filtern
Erscheinungsjahr
- 2019 (2) (entfernen)
Dokumenttyp
Sprache
- Englisch (2)
Schlagworte
- Gadolinium (2) (entfernen)
Organisationseinheit der BAM
Multiple sclerosis (MS) is the most common acquired neurological disease affecting Young adults. It leads to myelin destruction and formation of lesions in the brain and permeabilization of the blood-brain barrier (BBB).
Gadolinium based contrast agents (GBCA), used for diagnosis and monitoring by MRI, might accumulate in tissue, including brain. Using an animal model, application of linear and macrocyclic GBCA was investigated. Analysis was performed by laser ablation inductively coupled plasma (LA-ICP) MS. This method works as a bioimaging tool for sample thin sections and allows to identify regions of accumulated Gd in the samples.
In healthy and diseased mice, inflammationmediated changes in the brain were investigated by application of GBCA. The mean objective is to understand the changes in inflamed tissue and correlate alterations of the BBB by LA-ICP-MS (Imaging Mass Cytometry).
Recent recommendations by the Food and Drug Administration1 and the European Medicines Agency2 are to limit the clinical use of linear gadolinium-based contrast agents (GBCAs) due to convincing evidence of deposition in tissues. Macrocyclic GBCA continued to be considered safe, provided that patients have normal renal function. To date, given the low sensitivity of conventional MRI, there has been a debate about the signal increase following the injections of a macrocyclic GBCA.